Telithromycin for the treatment of acute exacerbations of chronic bronchitis.

摘要: Pooled data from three randomized, double-blind, multi- centre studies evaluated the efficacy and tolerability of telithromycin 800 mg once daily for 5 days vs. standard comparators (10-day amoxicillin-clavulanate 500/125 times daily, clarithromycin 500 or cefuroxime axetil twice daily) in outpatient treatment acute exacerbations chronic bronchitis. Per-protocol clinical cure rates at post-therapy/test (days 17-24) were 86.0 85.8% comparators, respectively, 79.1 78.7%, late post-therapy 31-36). Clinical comparable patients increased risk, including those > =65 years with severe infection significant airway obstruction (telithromycin, =77.1%; =75.0%). Telithromycin was well tolerated. Most adverse events considered possibly related to study medication gastrointestinal mild intensity. In conclusion, 5-day therapy is as effective tolerated 10-day comparators.